A 42-year-old man from a tribal area in Jharkhand visits the Sub-centre with a 2-week history of cough and low-grade fever. The health worker suspects tuberculosis and performs a sputum smear microscopy, which is positive for acid-fast bacilli (AFB). However, the Sub-centre does not have anti-tuberculous drugs or the capability to initiate directly observed therapy (DOT). What is the most appropriate next step in the management and referral pathway?

Explanation

## Tuberculosis Management in the Indian Public Health System **Key Point:** Tuberculosis is a notifiable disease managed under the **National Tuberculosis Elimination Programme (NTEP)**. While diagnosis can occur at any level (including Sub-centre), initiation of anti-tuberculous therapy and DOT must occur at a facility with adequate drug supply, trained personnel, and monitoring capacity—which is the PHC. ### TB Management Pathway in India ```mermaid flowchart TD A[Patient presents with TB symptoms]:::outcome --> B{Where does diagnosis occur?}:::decision B -->|Sub-centre| C[Sputum smear microscopy]:::action B -->|PHC/CHC| D[Sputum smear or GeneXpert MTB/RIF]:::action C -->|AFB positive| E[Refer to PHC for treatment initiation]:::action D -->|AFB positive| F[Initiate DOTS at PHC/CHC]:::action E --> G[PHC: Anti-TB drugs + DOT supervision]:::action F --> G G --> H[Monthly monitoring + sputum follow-up]:::action H --> I{Cure or Treatment completion?}:::decision I -->|Yes| J[Discharge from NTEP]:::outcome I -->|No| K[Refer to CHC/District TB Centre]:::urgent ``` ### Role of Each Facility in TB Management | Facility | TB Diagnostic Role | TB Treatment Role | DOT Supervision | |----------|-------------------|-------------------|------------------| | **Sub-centre** | Sputum collection, basic microscopy | None—referral only | No | | **PHC** | Sputum smear, GeneXpert MTB/RIF | First-line anti-TB drugs, initiation | Yes—trained health worker | | **CHC** | Sputum culture, drug sensitivity testing (DST) | Second-line drugs (MDR-TB), complex cases | Yes—TB health visitor | | **District TB Centre** | Specialized testing (culture, DST, CBNAAT) | MDR-TB, XDR-TB, treatment failure | Intensive DOT | ### Why PHC is the Correct Referral Point 1. **Drug supply:** PHC is the nodal agency for anti-tuberculous drug distribution under NTEP. Sub-centres do not stock these drugs. 2. **DOT capability:** PHC has trained health workers (ANM/ASHA) to supervise directly observed therapy, which is mandatory for TB treatment success. 3. **Monitoring:** PHC conducts monthly sputum follow-up, weight monitoring, and adverse effect surveillance. 4. **Decentralization:** NTEP emphasizes community-based DOT at the PHC level to improve treatment adherence and cure rates. 5. **Cost-effectiveness:** Outpatient DOT at PHC is more sustainable than inpatient hospitalization. **Clinical Pearl:** The **DOTS strategy** (Directly Observed Therapy, Short-course) is the cornerstone of TB control in India. DOTS at PHC level has achieved cure rates >85% and dramatically reduced TB mortality [cite:Park 26e Ch 3]. **High-Yield:** Sub-centre can **diagnose** TB (sputum collection, basic microscopy) but **cannot treat** it. Always refer AFB-positive cases to PHC for drug initiation and DOT. Self-medication or private drug purchase leads to drug resistance and treatment failure. **Warning:** ~~Inpatient hospitalization is routine for TB~~ — Most TB patients are managed as outpatients under DOTS at PHC. Hospitalization is reserved for severe complications (hemoptysis, TB meningitis) or treatment failure.